Immunoassay in healthcare testing applications.
Immunoassay is used extensively for drug testing in pain management. Drug testing for the purpose of compliance monitoring is fundamentally different from forensic applications, which may rely on immunoassay screening to rapidly identify "negative" samples. In clinical settings, focus is shifted from identification of select drugs of abuse with low positivity rates to detection of a wide variety of licit and illicit compounds with expected high positivity rates. The primary drug classes of interest in this population, opioids and benzodiazepines, require special testing considerations when immunoassay is used. This review highlights the performance characteristics of immunoassay, with special emphasis on prescription drug classes and testing at the point-of-care.
Aegis Sciences Corporation, Nashville, Tennessee; College of Pharmacy, University of Tennessee, Memphis, Tennessee.
Anne Z
AZ
DePriest
Aegis Sciences Corporation, Nashville, Tennessee; Department of Pathology, Immunology and Microbiology, Vanderbilt University, Nashville, Tennessee.
David L
DL
Black
Aegis Sciences Corporation, Nashville, Tennessee.
Timothy A
TA
Robert
D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use* / Q000652:urine; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use* / Q000652:urine; D015415:Biomarkers / Q000652:urine; D059350:Chronic Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000652:urine; D016903:Drug Monitoring / Q000379:methods*; D005188:False Negative Reactions; D005189:False Positive Reactions; D006801:Humans; D007118:Immunoassay; D009293:Opioid-Related Disorders / Q000175:diagnosis* / Q000652:urine; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D013048:Specimen Handling; D015813:Substance Abuse Detection / Q000379:methods*; D016482:Urinalysis
D000701:Analgesics, Opioid; D015415:Biomarkers; D001569:Benzodiazepines